Antibody Therapeutics Xchange - Philadelphia - 2025

As the world leader in antibody services, our decades of research experience converge with advanced AI to identify, engineer, and de-risk molecules for clinical readiness. With our expertise in rabbit antibody discovery, we harness cutting-edge technologies to generate high-affinity antibodies with exquisite specificity and deep characterization for a phenotypically rich output. Our AI-enabled, multiparametric in silico workflows such as paratope binning, epitope mapping, humanization and immunogenicity assessment are infinitely scalable and accelerate discovery while maximizing the natural immune repertoire’s benefits. Recent approvals of rabbit-derived humanized antibody drugs underscore its impact. Our fully integrated strategy sets a new standard in antibody development.

Our Activmab technology enables the direct incorporation of multi-pass membrane proteins such as GPC ...

Efficient bispecific antibody (bsAb) production requires precise assembly of multiple chains. Combining the knob-into-hole (KiH) mutation set with Lonza’s bYlok® bsAb pairing technology, evitria AG achieves >95% heterodimer purity and <5% aggregation using a single Protein-A purification step. Further, proprietary, in-house ion exchange (IEX) chromatography further streamlines polishing for applications beyond early R&D, including large-scale animal studies. Leveraging 15 years and over 130,000 protein production runs, evitria AG offers rapid development of diverse, high-quality bsAb panels.

The antibody response to vaccination and infection is key to immune defense and human antibody therapeutic development, offering a blueprint for targeted treatments. While B-cell sequencing aids human antibody discovery, it may miss the full diversity of circulating antibodies, as only 2-3% of B cells are in circulation, and not all produce antibodies. We demonstrate a mass spectrometry proteomics-based approach to sequencing neutralizing antibodies from serum of a patient vaccinated against SARS-CoV-2. Following de novo sequencing, we recombinantly expressed 12 antibodies. Six recombinant antibodies exhibited similar or higher binding affinities than the original natural polyclonal antibody and exhibited neutralizing capabilities.

Choosing and changing partners: What is the desired biological mechanism of action? Bispecific or Co ...

What factors influence the immunogenicity of therapeutic antibodies in vivo? How useful are in silic ...

Which developability assays are most informative for assessing candidates early on? -for stability, ...

Lead generation as a commodity? What challenges remain Diversity and ML-based selections:  Never do ...

Affinity maturation to enhance the binding affinity of therapeutic monoclonal antibody (mAb). Develo ...

Off-target binding is a significant hurdle in the development of antibody-based therapies, contribut ...